title: Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.
abstract: Clear cell carcinomas of the uterine corpus and cervix are rare gynecological cancers with limited information regarding the pathogenesis and biology. At present, the approach to management is the same as for patients with the more common histological subtypes of endometrioid endometrial cancer and adenocarcinoma of the cervix. Surgical resection is the standard treatment for patients with early-stage disease, but there is no evidence-based approach to direct the management of patients with more advanced-stage disease at presentation or with recurrent disease. We review the epidemiology, pathology, and what is known about both uterine corpus and cervical clear cell cancers and make management recommendations.
authors.affiliation: *Saitama Medical University International Medical Center, Saitama, Japan (GOTIC); †Hyogo Cancer Center, Akashi, Japan (GOTIC); ‡Harvard Medical School, Boston, MA (RTOG); §Southern General Hospital, Glasgow, Lanarkshire, UK; ¶Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK (SGCTG); ∥Hospices Civils de Lyon, Lyon, France (GINECO); #Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada (GOG); **Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy (MITO); ††Kliniken Essen Mitte, Essen, Germany (AGO); ‡‡Seoul National University College of Medicine, Seoul, Korea (KGOG); §§Institut Claudius Regaud, Toulouse, France (GINECO); ¶¶Instituto Nazionale Tumori, Napoli, Italy (MITO); and ∥∥Prince of Wales Hospital, Sydney, Australia (ANZGOG).
authors.forename: Kosei
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Shoji
authors.initials: S
authors.lastname: Nagao
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuda
authors.forename: David
authors.initials: D
authors.lastname: Millan
authors.forename: Akila N
authors.initials: AN
authors.lastname: Viswanathan
authors.forename: Rosalind M
authors.initials: RM
authors.lastname: Glasspool
authors.forename: Mojgan
authors.initials: M
authors.lastname: Devouassoux-Shisheboran
authors.forename: Alan
authors.initials: A
authors.lastname: Covens
authors.forename: Domenica
authors.initials: D
authors.lastname: Lorusso
authors.forename: Christian
authors.initials: C
authors.lastname: Kurzeder
authors.forename: Jae-Weon
authors.initials: JW
authors.lastname: Kim
authors.forename: Laurence
authors.initials: L
authors.lastname: Gladieff
authors.forename: Jane
authors.initials: J
authors.lastname: Bryce
authors.forename: Michael
authors.initials: M
authors.lastname: Friedlander
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008495:Medical Oncology; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014594:Uterine Neoplasms / Q000473:pathology* / Q000628:therapy